Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reproductive Lifespan and Adult-Onset Bronchiectasis in U.S. Postmenopausal Women: An Investigation of the Women's Health Initiative Cohort.

Chronic obstructive pulmonary diseases (Miami, Fla.)·2026
Same author

In Pursuit of Excellence: The Past, Present, and Future of Quality Improvement in Pneumonia.

Clinics in chest medicine·2026
Same author

Cystic Fibrosis Transmembrane Conductance Regulator Mutations and Potential Associations With Increased Rates of Pulmonary Infections Among Patients from the US Bronchiectasis and NTM Research Registry.

Chest·2026
Same author

Association of Chronic Rhinosinusitis and <i>Pseudomonas Aeruginosa</i> in Sputum of Patients With Non-Cystic Fibrosis Bronchiectasis.

Chronic obstructive pulmonary diseases (Miami, Fla.)·2026
Same author

Anti-inflammatory therapies for bronchiectasis.

Current opinion in infectious diseases·2026
Same author

Efficacy and safety of brensocatib in Japanese patients with non-cystic fibrosis bronchiectasis: Analysis of the ASPEN trial.

Respiratory investigation·2026

Related Experiment Video

Updated: Jun 13, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

New treatment options for bronchiectasis.

Mark L Metersky1

  • 1Division of Pulmonary and Critical Care Medicine, University of Connecticut School of Medicine, Farmington, CT 06030-1321, USA. Metersky@nso.uchc.edu

Therapeutic Advances in Respiratory Disease
|April 15, 2010
PubMed
Summary
This summary is machine-generated.

New therapies for non-cystic fibrosis bronchiectasis are under investigation. While some show promise, like inhaled antibiotics and macrolides, more conclusive evidence is needed for routine use.

Related Experiment Videos

Last Updated: Jun 13, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Pharmacology

Background:

  • Therapies for cystic fibrosis are sometimes used for bronchiectasis without proven benefit.
  • There is growing interest in developing and validating new treatments for non-cystic fibrosis bronchiectasis.

Purpose of the Study:

  • To review current and emerging therapies for non-cystic fibrosis bronchiectasis.
  • To assess the evidence for inhaled antibiotics, hyperosmolar agents, and macrolides in bronchiectasis management.

Main Methods:

  • Review of existing literature on therapies for non-cystic fibrosis bronchiectasis.
  • Analysis of clinical trial data and preliminary findings for inhaled tobramycin, aztreonam, ciprofloxacin, hypertonic saline, mannitol, and macrolides.

Main Results:

  • Inhaled tobramycin shows microbiologic improvement but limited outcome benefit, partly due to bronchospasm.
  • Data on inhaled aztreonam and ciprofloxacin are pending, though microbiologic results are promising.
  • Hyperosmolar agents show promise but are not yet recommended for routine use.
  • Macrolides possess anti-inflammatory properties and are increasingly used, with some studies supporting their benefit despite methodological flaws.

Conclusions:

  • Current evidence for many novel therapies in non-cystic fibrosis bronchiectasis is limited.
  • Chronic low-dose macrolide therapy is common but requires more conclusive evidence.
  • Further research is needed to establish definitive benefits and optimal use of emerging treatments.